Literature DB >> 32171330

Targeted deep amplicon sequencing of kelch 13 and cytochrome b in Plasmodium falciparum isolates from an endemic African country using the Malaria Resistance Surveillance (MaRS) protocol.

Mariangela L'Episcopia1, Julia Kelley2, Dhruviben Patel2, Sarah Schmedes3, Shashidahar Ravishankar4, Michela Menegon5, Edvige Perrotti5, Abduselam M Nurahmed6, Albadawi A Talha7,8, Bakri Y Nour9, Naomi Lucchi10, Carlo Severini5, Eldin Talundzic10.   

Abstract

BACKGROUND: Routine molecular surveillance for imported drug-resistant malaria parasites to the USA and European Union is an important public health activity. The obtained molecular data are used to help keep chemoprophylaxis and treatment guidelines up to date for persons traveling to malaria endemic countries. Recent advances in next-generation sequencing (NGS) technologies provide a new and effective way of tracking malaria drug-resistant parasites.
METHODS: As part of a technology transfer arrangement between the CDC Malaria Branch and the Istituto Superiore di Sanità (ISS), Rome, Italy, the recently described Malaria Resistance Surveillance (MaRS) protocol was used to genotype 148 Plasmodium falciparum isolates from Eritrea for kelch 13 (k13) and cytochrome b (cytb) genes, molecular markers associated with resistance to artemisinin (ART) and atovaquone/proguanil (AP), respectively.
RESULTS: Spanning the full-length k13 gene, seven non-synonymous single nucleotide polymorphisms (SNPs) were found (K189N, K189T, E208K, D281V, E401Q, R622I and T535M), of which none have been associated with artemisinin resistance. No mutations were found in cytochrome b.
CONCLUSION: All patients successfully genotyped carried parasites susceptible to ART and AP treatment. Future studies between CDC Malaria Branch and ISS are planned to expand the MaRS system, including data sharing, in an effort to maintain up to date treatment guidelines for travelers to malaria endemic countries.

Entities:  

Keywords:  Drug resistance; Molecular surveillance; Next-generation sequencing; Plasmodium falciparum

Year:  2020        PMID: 32171330     DOI: 10.1186/s13071-020-4005-7

Source DB:  PubMed          Journal:  Parasit Vectors        ISSN: 1756-3305            Impact factor:   3.876


  3 in total

Review 1.  Antimalarial Drug Resistance and Implications for the WHO Global Technical Strategy.

Authors:  Matthew M Ippolito; Kara A Moser; Jean-Bertin Bukasa Kabuya; Clark Cunningham; Jonathan J Juliano
Journal:  Curr Epidemiol Rep       Date:  2021-03-14

Review 2.  Prevalence of potential mediators of artemisinin resistance in African isolates of Plasmodium falciparum.

Authors:  Afolabi Owoloye; Michael Olufemi; Emmanuel T Idowu; Kolapo M Oyebola
Journal:  Malar J       Date:  2021-12-02       Impact factor: 3.469

3.  Mutation in the Plasmodium falciparum BTB/POZ Domain of K13 Protein Confers Artemisinin Resistance.

Authors:  Lucie Paloque; Romain Coppée; Barbara H Stokes; Nina F Gnädig; Karamoko Niaré; Jean-Michel Augereau; David A Fidock; Jérôme Clain; Françoise Benoit-Vical
Journal:  Antimicrob Agents Chemother       Date:  2021-10-04       Impact factor: 5.191

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.